Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADMA Biologics

22.19
+0.46002.12%
Volume:1.10M
Turnover:24.24M
Market Cap:5.27B
PE:27.40
High:22.30
Open:21.84
Low:21.80
Close:21.73
Loading ...
Dec 07, 2022

Major Issues Report

8-K - Current report
Dec 06, 2022

Major Issues Report

8-K - Current report
Nov 09, 2022

Major Issues Report

8-K - Current report
Nov 09, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 31, 2022

Major Issues Report

8-K - Current report
Aug 10, 2022

Major Issues Report

8-K - Current report
Aug 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 22, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 22, 2022

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 28, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 27, 2022

Major Issues Report

8-K - Current report
Jun 21, 2022

Major Issues Report

8-K - Current report
Jun 13, 2022

Major Issues Report

8-K - Current report
May 11, 2022

Major Issues Report

8-K - Current report